Experts say GLP-1 drugs may be lowering U.S. obesity rates, but broader reforms are needed
सिर्फ तथ्य

Experts say GLP-1 drugs may be lowering U.S. obesity rates, but broader reforms are needed

सारांश

A JAMA Summit report suggests that widespread use of GLP-1 receptor agonists could be contributing to a recent decline in U.S. obesity prevalence, while emphasizing that lasting progress requires changes to food environments, healthcare access, and stigma reduction.

A multidisciplinary group of clinicians, scientists, economists, policymakers and patient advocates released a special communication in JAMA outlining a strategy to curb the global obesity epidemic. The report, based on discussions at the May 2026 JAMA Summit on Obesity, highlights biological, socioeconomic and environmental drivers of obesity and evaluates the impact of newer medications and public-health interventions.

National data from 2021-2023 show that about two-in-five U.S. adults and one-in-five children and adolescents have obesity. The authors note that an estimated one in nine U.S. adults is now using glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and they suggest that this widespread adoption may be contributing to a modest decline in U.S. obesity prevalence for the first time in decades, even as severe obesity continues to rise.

"GLP-1 receptor agonists act on hormone receptors to reduce hunger and increase satiety, and clinical trials have documented cardiovascular, metabolic, kidney and liver benefits in selected patients," the report states.

The authors caution that high drug costs, restrictive insurance approvals, gastrointestinal side effects, gallbladder disease and high discontinuation rates limit the long-term public-health impact of these medications. They also warn about safety concerns surrounding unapproved compounded alternatives.

Beyond pharmacotherapy, the report calls for coordinated reforms, including food-packaging warning labels, restrictions on unhealthy food marketing to children, stronger nutrition assistance programs, healthier school meals, and expanded opportunities for physical activity. It stresses the need to expand insurance coverage for multidisciplinary care, train clinicians to provide weight-bias-free treatment, and address socioeconomic barriers that disproportionately affect disadvantaged populations.

The authors conclude that treating obesity as a chronic disease with biological, behavioral and environmental determinants requires both medical interventions and systemic public-health policies to achieve lasting reductions in prevalence and related health complications.

स्रोत

News-Medical

पढ़ते रहें — निःशुल्क

समाचार फ़ॉलो करने के लिए मुफ़्त खाता बनाएँ। कार्ड की आवश्यकता नहीं।